*GG*
senior member
- Messages
- 6,389
- Location
- Concord, NH
NORD will co-sponsor the 1st Annual Rare Diseases/Orphan Products Summit on Oct. 11-13, under the auspices of the Drug Information Association (DIA). Collaborating organizations include EURORDIS (the European Rare Disease Organization), FDA, NIH, and the Duke Clinical Research Institute. Register Here >
Come and Meet...
Francis Collins,Director of the National Institutes of Health (NIH)
Michael Astrue, Commissioner of Social Security Administration
Janet Woodcock, Director, FDA Center for Drug Evaluation and Research
Mark McClellan, former FDA Commissioner
John Crowley, Chairman and CEO of Amicus
In addition to plenary sessions to which senior government, industry, and patient representatives are being invited to speak, there will be three tracks at the meeting:
Track A will be for academic and industry investigators and will build on a three-day rare-disease investigator training course first offered in October 2010
Track B will be for patients and patient organizations
Track C will be for industry and the investment community
Special attention will be paid to innovations in orphan product development such as biomarkers, registries, natural histories and use of social media. In addition, there will be opportunities for networking and for exhibitors.
This international summit will provide a unique opportunity for all stakeholders in the rare disease and orphan product space to learn and to develop a joint agenda.
http://www.rarediseases.org/news-events/news/2011-summit
Come and Meet...
Francis Collins,Director of the National Institutes of Health (NIH)
Michael Astrue, Commissioner of Social Security Administration
Janet Woodcock, Director, FDA Center for Drug Evaluation and Research
Mark McClellan, former FDA Commissioner
John Crowley, Chairman and CEO of Amicus
In addition to plenary sessions to which senior government, industry, and patient representatives are being invited to speak, there will be three tracks at the meeting:
Track A will be for academic and industry investigators and will build on a three-day rare-disease investigator training course first offered in October 2010
Track B will be for patients and patient organizations
Track C will be for industry and the investment community
Special attention will be paid to innovations in orphan product development such as biomarkers, registries, natural histories and use of social media. In addition, there will be opportunities for networking and for exhibitors.
This international summit will provide a unique opportunity for all stakeholders in the rare disease and orphan product space to learn and to develop a joint agenda.
http://www.rarediseases.org/news-events/news/2011-summit
